LATEST ARTICLES
- Thermo Fisher to buy research contractor PPD in $17B deal
- Cancer biotech Tango to go public through $350M SPAC deal
- Sage, Biogen drug reduces tremors but side effects could limit potential
- GSK stops studies testing closely watched cancer immunotherapy
- Moderna watches for ‘waning immunity’ as new data show durable vaccine protection
- Merck, in latest COVID-19 setback, scraps one drug and pins hopes on another
- Lilly claims promising finding in failed study of COVID-19 drug
- With new data, Merck could be first to bring immunotherapy to early kidney cancer
- Biogen adds a late-stage prospect to its growing biosimilar business
- Gilead wins full approval for drug acquired in Immunomedics deal
